See more : Amvis Holdings, Inc. (7071.T) Income Statement Analysis – Financial Results
Complete financial analysis of PCI Biotech Holding ASA (PCIB.OL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PCI Biotech Holding ASA, a leading company in the Biotechnology industry within the Healthcare sector.
- AB SKF (publ) (SKF-B.ST) Income Statement Analysis – Financial Results
- FIH Mobile Limited (FXCNY) Income Statement Analysis – Financial Results
- Pasupati Acrylon Limited (PASUPTAC.NS) Income Statement Analysis – Financial Results
- Future Link Network Co.,Ltd. (9241.T) Income Statement Analysis – Financial Results
- Evertz Technologies Limited (EVTZF) Income Statement Analysis – Financial Results
PCI Biotech Holding ASA (PCIB.OL)
About PCI Biotech Holding ASA
PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company develops anticancer paradigms, including fimaCHEM, a chemotherapeutics for treatment of cancer; fimaVACC, a T-cell induction technology for therapeutic vaccination, which is in Phase I clinical study; and fimaNAc, a nucleic acid therapeutics delivery technology, which is in pre-clinical study. It also offers Amphinex, a photosensitiser fimaporfin. The company has collaborative research programs with Bavarian Nordic, BioNTech, Phio Pharmaceuticals, DCprime, eTheRNA immunotherapies, IMV, and Aposense. PCI Biotech Holding ASA is based in Oslo, Norway.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 2.99M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.42M | 10.44M | 8.61M | 7.37M |
Cost of Revenue | 0.00 | 633.00K | 2.54M | 2.21M | 955.00K | 5.00K | 6.00K | 15.89M | 15.31M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 2.99M | -633.00K | -2.54M | -2.21M | -955.00K | -5.00K | -6.00K | -15.89M | -15.31M | 0.00 | 0.00 | 0.00 | 7.42M | 10.44M | 8.61M | 7.37M |
Gross Profit Ratio | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% |
Research & Development | 15.63M | 44.76M | 71.71M | 75.57M | 83.31M | 40.34M | 40.99M | 39.22M | 38.84M | 39.34M | 32.79M | 31.26M | 22.23M | 20.19M | 19.32M | 14.32M |
General & Administrative | 9.60M | 16.44M | 20.60M | 13.92M | 14.88M | 13.77M | 12.69M | 4.29M | 4.25M | 4.43M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 9.60M | 16.44M | 20.60M | 13.92M | 14.88M | 13.77M | 12.69M | 4.29M | 4.25M | 4.43M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Expenses | 0.00 | -4.75M | -6.27M | -7.37M | -9.39M | -9.59M | -10.25M | -10.48M | -10.47M | -7.28M | -3.46M | -3.91M | 2.27M | 6.50M | 6.98M | 5.18M |
Operating Expenses | 25.23M | 56.45M | 86.03M | 82.12M | 88.80M | 44.52M | 43.43M | 33.03M | 32.63M | 36.49M | 29.33M | 27.36M | 24.50M | 26.69M | 26.30M | 19.51M |
Cost & Expenses | 25.23M | 56.45M | 86.03M | 82.12M | 88.80M | 44.52M | 43.43M | 33.03M | 32.63M | 36.49M | 29.33M | 27.36M | 24.50M | 26.69M | 26.30M | 19.51M |
Interest Income | 2.09M | 1.24M | 640.00K | 1.85M | 2.40M | 740.00K | 677.00K | 447.00K | 867.00K | 812.00K | 1.72M | 2.32M | 0.00 | 2.31M | 2.63M | 932.00K |
Interest Expense | 160.00K | 127.00K | 89.00K | 397.00K | 506.00K | 117.00K | 0.00 | 4.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.00K | -41.00K | 169.00K |
Depreciation & Amortization | 19.00K | 633.00K | 2.54M | 2.21M | 955.00K | 5.00K | 6.00K | 5.00K | 4.00K | 4.00K | 4.00K | 17.00K | 61.00K | 102.00K | 128.00K | 71.00K |
EBITDA | -22.22M | -54.10M | -82.70M | -69.63M | -85.11M | -44.51M | -43.43M | -33.02M | -32.63M | -36.47M | -29.32M | -25.24M | -13.69M | -16.14M | -17.56M | -12.07M |
EBITDA Ratio | -743.21% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -229.22% | -154.55% | -203.88% | -163.80% |
Operating Income | -22.24M | -56.45M | -86.03M | -82.12M | -88.80M | -44.52M | -43.43M | -33.03M | -32.63M | -36.47M | -29.33M | -27.35M | -17.08M | -16.24M | -17.69M | -12.14M |
Operating Income Ratio | -743.85% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -230.04% | -155.52% | -205.36% | -164.76% |
Total Other Income/Expenses | 1.93M | 1.35M | -2.36M | 9.88M | 58.00K | 9.74M | 590.00K | 843.00K | 707.00K | 632.00K | 1.72M | 2.10M | 3.33M | 2.30M | 2.67M | 763.00K |
Income Before Tax | -20.32M | -55.10M | -88.39M | -72.24M | -88.75M | -34.78M | -42.84M | -32.18M | -31.92M | -35.84M | -27.61M | -25.26M | -13.75M | -13.94M | -15.02M | -11.38M |
Income Before Tax Ratio | -679.43% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -185.22% | -133.47% | -174.35% | -154.40% |
Income Tax Expense | 0.00 | -1.35M | 89.00K | 397.00K | 506.00K | 9.86M | 590.00K | 847.00K | 707.00K | 650.00K | 1.72M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income | -20.32M | -53.74M | -88.48M | -72.64M | -89.25M | -34.78M | -42.84M | -32.18M | -31.92M | -35.84M | -27.61M | -25.26M | -13.75M | -13.94M | -15.02M | -11.38M |
Net Income Ratio | -679.43% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -185.22% | -133.47% | -174.35% | -154.40% |
EPS | -0.54 | -1.44 | -2.37 | -1.95 | -2.40 | -1.25 | -1.76 | -2.01 | -2.12 | -3.22 | -2.14 | -1.97 | -1.07 | -1.26 | -1.65 | -1.50 |
EPS Diluted | -0.54 | -1.44 | -2.37 | -1.95 | -2.40 | -1.23 | -1.73 | -1.99 | -2.11 | -3.04 | -2.02 | -1.85 | -0.98 | -1.17 | -1.65 | -1.50 |
Weighted Avg Shares Out | 37.33M | 37.33M | 37.33M | 37.29M | 37.23M | 27.80M | 24.35M | 16.05M | 15.04M | 11.13M | 12.90M | 12.85M | 12.85M | 11.08M | 9.08M | 7.57M |
Weighted Avg Shares Out (Dil) | 37.33M | 37.33M | 37.33M | 37.29M | 37.23M | 28.35M | 24.83M | 16.16M | 15.11M | 11.78M | 13.68M | 13.67M | 14.06M | 11.96M | 9.08M | 7.57M |
Source: https://incomestatements.info
Category: Stock Reports